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Abstract Mammographically-detected breast arterial calcifi-
cations (BAC) are considered to be an incidental finding
without clinical importance since they are not associated with
increased risk of breast cancer. The goal of this article is to
review existing evidence that the presence of BAC on mam-
mography correlates with several (but not all) traditional car-
diovascular disease (CVD) risk factors and with prevalent and
incident CVD. Thus, BAC detected during routine mammog-
raphy is a noteworthy finding that could be valuable in iden-
tifying asymptomatic women at increased future CVD risk
that may be candidates for more aggressive management. In
addition, there are notable differences in measures of subclin-
ical atherosclerosis burden in women (ie, coronary artery
calcification) by race/ethnic background, and the same
appears to be true for BAC, although data are very limited.
Another noteworthy limitation of prior research on BAC is the
reliance on absence vs presence of BAC; no study to date has
determined gradation of BAC. Further research is thus re-
quired to elucidate the role of BAC gradation in the prediction
of CVD outcomes and to determine whether adding BAC
gradation to predictionmodels based on traditional risk factors
improves classification of CVD risk.
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Mammography
Introduction
Although the value of mammographic screening before age 50
and after age 74 has recently been called into question by the
US Preventive Services Task Force [1] current clinical practice
guidelines recommend annual mammographic screening of all
women aged 40 years or older for early detection of breast
cancer. However, important information about the presence and
severity of subclinical atherosclerosis that is available in mam-
mograms is presently ignored during mammographic assess-
ments. Specifically, this information includes the presence of
breast arterial calcification (BAC), which has been shown to be
associated with risk of cardiovascular disease (CVD) morbid-
ity, and mortality. Such information may be useful for improve-
ment of CVD risk stratification in a similar manner that
coronary artery calcification (CAC) has been shown in numer-
ous prospective studies. Data from CARDIA [2], MESA [3],
and other population-based studies indicate that the extent of
CAC in women differs importantly by ethnic background, and
the same appears to be true for calcification in other vascular
beds including the breast, but the data available are very
limited.
The leading causes of death among women in the US are
heart disease, cancer, and stroke [4]. Even though remark-
able advances have been made in the field of CVD preven-
tion, for many asymptomatic individuals the first
manifestation of underlying disease is an unexpected acute
myocardial infarction or sudden death [5, 6]. Furthermore,
prior studies have shown that women with obstructive cor-
onary disease have worse prognosis after acute myocardial
infarction compared with men [7–11]. Awidespread tool for
CVD risk stratification is the Framingham risk score, which
classifies patients into low (10–year CVD risk<10 %), in-
termediate (10–year CVD risk 10 %–20 %) and high (10–
year CVD risk>20 %) risk groups based on traditional risk
factors [12]. However, published data indicate that up to
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20 % of all coronary events occur in the absence of these
major risk factors and that 60 % of events are experienced
by low-to-intermediate risk patients [13–15]. Therefore,
there is great interest in developing new methods, including
novel serum biomarkers and noninvasive imaging modali-
ties, to better identify patients who may be appropriate
candidates for more aggressive primary prevention [16,
17]. A new algorithm, the Reynolds Risk Score, has been
recently developed and (internally) validated in the
Women’s Health Study [18].
Several non-invasive imaging techniques have been eval-
uated [19–21]. While ultrasound- and MRI-based techni-
ques rely primarily on images of abnormal vessel anatomy
due to atherosclerosis, the CT-based approach is based on
estimating vascular calcium deposition. Although all these
imaging techniques, particularly CT, appear to predict CVD
risk in multiple longitudinal cohort studies [22, 23], critical
barriers for widespread use of these imaging modalities are
high cost, need for specific types of equipment, and/or
specially trained personnel. In addition, concerns have been
raised about increased cancer risk following cardiac CT
[24], although it should be pointed out that radiation con-
cerns are mainly for higher dosage coronary CT angiogra-
phy and that radiation from a mammogram vs coronary
calcium scan are very similar (0.7–0.9 mSV). BAC detected
by widely used mammography in women thus offer a po-
tential new tool for detecting subclinical CVD which may
add incremental prognostic value beyond the existing CVD
risk classification schemes without additional radiation ex-
posure and cost.
Mammographically-Detected Calcifications
Mammography is a proven tool for early detection of breast
cancer that is associatedwith a decrease inmortality rates [25].
The American Cancer Society presently recommends that “all
women age 40 and older should have a screening mammo-
gram every year and should continue to do so for as long as
they are in good health”. National data indicate that at least
75 % of women age 40 and over have attended a mammo-
graphic exam in the last 2 years and 50 % have had a mam-
mogram in the past year [26]. This tallies up to 42 million
women over the age of 50. Under managed care, mammog-
raphy attendance is over 80 % [27]. The attendance to mam-
mographic screening is lower among uninsured, low SES
women compared with women in managed care, but mam-
mography is the most common screening test in women,
regardless of insurance status. In the 2005 National Health
Interview Survey, the self-reported attendance for mammog-
raphy was 66 % [28]. In the Pennsylvania Centers for Disease
Control Behavioral Risk Factor Survey, 64 % of women with
less than a high school education self-reported ever having a
mammogram [29]. As established in legislation, Medicare and
Medicaid provide conditions of coverage for both screening
and diagnostic plain film and digital mammography services.
Of note, up to 40% of breast cancers detected by screening are
manifested by microcalcifications as the sole mammographic
lesion [30]. As a result, the modern mammographic equip-
ment is designed specifically for the detection of microcalci-
fications [31]. Therefore, this routine screening tool provides a
unique opportunity to detect BAC as a possible mammo-
graphic sign of atherosclerosis. BAC on the mammogram is
identifiable as linear, parallel lines that resemble a railroad
track (see Fig. 1).
Vascular Calcification Pathology: Medial vs Intimal
Calcification occurs at 2 anatomic sites within the vascular
wall: the intima, where it is invariably associated with
atherosclerosis, and the media. These different locations
most likely represent 2 pathophysiologically different pro-
cesses [32–34]. Intimal calcification is an active, regulated
process that is similar to bone formation and involves ex-
pression of growth factors, matrix proteins, and other bone-
related proteins [35], and has been associated with inflam-
matory cells, lipid deposits, and vascular smooth muscle
cells. By contrast, medial arterial or Mönckeberg-type cal-
cification occurs in the absence of macrophages or lipid
deposits [36] and has been described in the context of aging,
diabetes, end-stage renal disease, neuropathy, and a number
of rare genetic syndromes [37–40]. A study of medial cal-
cification among Pima Indians showed it to be significantly
associated with type II diabetes and with increased CVD
mortality [41]. Additional studies have confirmed that me-
dial calcification is an independent predictor of CVD events
in patients with diabetes or end-stage renal disease [42–44].
Fig. 1 Detail of a lateral mammogram. The arrow shows a linear
tubular calcification along the contours of the arterial wall
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The proposed putative mechanism by which medial calcifi-
cation may increase CVD risk is increased arterial stiffness.
Consistent with this notion, elastin has been shown to have a
strong affinity for calcium and it has been postulated that
disruption of the elastic fibers promotes medial calcification
[45]. In a pathology study, BAC were localized in the tunica
media, but some arteries showed intimal thickening in some
cases [46]. With conventional x-ray techniques or with
modern digital mammography, it is not possible to differen-
tiate with certainty between intimal and medial calcifica-
tions, although the appearance of medial calcifications is
more fine and diffused in smaller vessels, compared with the
large and discontinuous appearance of intimal calcifications
in large and medium size arteries [47, 48]. BAC is mostly
(but not entirely) medial, a non-obstructive condition lead-
ing to reduced arterial compliance.
Prevalence of BAC on Mammography
The prevalence of BAC in previously published studies
varies from 1 % to 49 %. Such large differences may be
explained by heterogeneity in the studied populations, var-
iations in sensitivity of mammography equipment and
reporting bias. Age is the most powerful factor influencing
the prevalence of BAC [49, 50]. Pre-existing coronary artery
disease is also related to higher prevalence of BAC [51].
Race/ethnicity is another significant factor in the prevalence
of BAC. In a large cohort of women aged 32–92 years who
attended routine mammography, Hispanic women had the
highest prevalence (34 %), whereas Asian women had the
lowest (7 %), vs 24 % in White women, and 25 % in
African-American women [52].
Relation of BAC to Cardiovascular Risk Factors
and Other Factors
Prior studies have reported associations of BAC presence
with older age [49, 52–59], diabetes [55, 58–60], body mass
index [61], hypertension [54, 61–63], albuminuria [61],
triglycerides [64], homocysteine [64], and hs-CRP [64]. It
has been postulated that hyperglycemia may induce medial
calcium deposits by upregulating the production of osteo-
genic proteins such as matrix Gla protein, osteocalcin, and
osteoprotegerin [65, 66]. A recent study demonstrated that
BAC also correlates with the duration of diabetes [67].
Surprisingly, an inverse association between smoking and
BAC has been found by several studies [55, 56, 61, 68].
Another study has also reported an association of BAC with
spontaneous or artificial menopause [49]. In the European
Prospective Investigation into Cancer and Nutrition Study
among women aged 49–70 years, BAC was associated with
greater parity and with a history of lactation [68]. The
authors speculated that both pregnancy and breast feeding
induce transient hypercalcemia to meet requirements for
fetal growth and breast milk production [69]. Duration of
lactation has been associated with lower prevalence of the
metabolic syndrome in midlife, making the BAC-lactation
relationship somewhat paradoxical [70]. A significant in-
verse association has been reported between menopausal
hormonal therapy and BAC in 4 studies [55, 71–73].
These data underscore a resemblance between BAC and
coronary atherosclerosis, since increased duration of hor-
monal therapy has been shown to be associated with lower
prevalence of CAC [74]. Mild to moderate impairment of
renal function has been associated with clinical CAD [75]
and with coronary and peripheral atherosclerosis [76].
However, there are no studies that have examined the rela-
tionship between renal function and BAC. Although there is
a growing recognition of the importance of sleep parameters
in subclinical and clinical coronary disease [77–81], no
study to date has examined the association of obstructive
sleep apnea or sleep duration with BAC.
Recent studies indicate that vitamin D deficiency is asso-
ciated with increased risk of CVD independently of estab-
lished risk factors [82–84]. Vascular calcification, along with
influences on blood pressure regulation, glycemic control, and
inflammation has been proposed as one of the potential mech-
anisms behind the vitamin D-CVD relationship, yet evidence
of an association between vitamin D status and vascular
calcification, including BAC, is lacking. Elevated serum cal-
cium (C) levels have been suggested to be a risk factor for
atherosclerosis [85] and myocardial infarction [86]. In turn,
high serum phosphorus (P), high serum C x P product, and
hyperparathyroidism influence the prevalence of vascular cal-
cification, particularly in end-stage renal disease patients [87].
However, the association between these mineral metabolism
factors and BAC has never been investigated. Statins have
been shown in observational studies to be associated with
reduced progression of CAC [88, 89], but clinical trials
addressing the question of whether statins retard CAC pro-
gression have been disappointing [90, 91]. Emerging evidence
indicates that nitrogen-containing bisphosphonates exert ben-
eficial pleiotropic effects in the CVD system including reduc-
tion of lipids [92], inflammation [93], and inhibition of
vascular calcification [94].
Arterial calcification and osteoporosis commonly ac-
company one another in postmenopausal women. A re-
cent study has demonstrated that BAC is associated with
osteoporotic vertebral fractures in Japanese women [95].
The results suggest that BAC and osteoporotic fractures
may share a common metabolic pathway in their patho-
genesis. These finding are consistent with prior work
demonstrating an association between reduced bone min-
eral density and BAC [96].
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Association of BAC with Clinical and Sub-clinical CVD
Outcomes
To date, 17 studies (4 prospective and 13 cross-sectional)
have been published relating BAC to clinical or subclinical
CVD (Table 1). The 4 cohort studies in Dutch [61, 72] and
US populations [55, 97] show consistent associations of
moderate strength between BAC presence and incident
non-fatal and fatal CVD. Adjusted odds ratios for cross-
sectional studies of the relationship between BAC presence
and prevalent CHD/CVD or angiographic coronary disease
are more heterogeneous, ranging from 1.0 to 8.1 [54,
98–102]. Of note, 1 study found no independent association
between BAC and angiographically-defined coronary dis-
ease [54]. Recently, Abi Rafeh et al. have published a meta-
analysis of previous studies evaluating BAC as a risk mark-
er for coronary artery disease that included 927 patients.
There was a 1.59 (95 % confidence interval [CI] 1–21–2.09)
increased odds of angiographically defined CAD in patients
with BAC seen on mammography [103••]. To date, 1 study
has demonstrated significant associations of BAC presence
with CAC [57], 2 with carotid intimal-media thickness (C-
IMT) [63, 104•], and 1 with positive brain MRI findings
[105••]. In the Maas et al. study among 499 women aged
49–70 years, BAC was associated with coronary arterial
calcifications after 9 years follow-up (OR 2.1, 95 % CI
1.10–4.23 after adjustment for age at baseline duration of
follow-up) [57]. In the Sedighi et al. study, compared with
women with C-IMT<0.6 mm, women with 0.6 mm≤C-IMT
≤0.8 mm, and with C-IMT>0.8 mm had multivariate odds
ratios (95 % CI) of 4.88 (1.47–16.16) and 23.36 (4.54–
120.14) of having any BAC, respectively [63]. The cova-
riates in the model included age, parity, menopausal status,
history of CAD, hypertension, diabetes, and smoking.
Yildiz et al. reported that BAC on mammography was
associated with C-IMT independently of age, parity, post-
menopausal duration, diabetes, systolic blood pressure, fast-
ing glucose, and triglyceride levels [104•]. Taken together,
these studies highlight the potential of BAC for predicting
clinical and sub-clinical CVD.
Multiethnic Study of Breast Arterial Calcium Gradation
and Cardiovascular Risk (MINERVA)
Researchers at the Kaiser Permanente Division of Research
in Northern California and at the University of California at
Irvine have recently launched MINERVA, a new prospec-
tive 5-year cohort study funded by the National Heart, Lung,
and Blood Institute (RO1HL106-043) that will yield novel
insights into ethnic differences in BAC presence and grada-
tion as well as into factors associated with BAC. But more
importantly, MINERVA will shed light on the potential
value of BAC gradation as a new tool for CVD risk strati-
fication and thus for CVD prevention. Hence, MINERVA’s
findings will break new ground and could have considerable
clinical and public health significance for the millions of
women who routinely undergo mammographic screening.
MINERVA was designed with 3 specific aims in mind:
(1) To establish a multi-ethnic cohort (n=5400) of women
between the ages of 60 and 79 years with equal repre-
sentation of Caucasian (n=1350; 25 %), African-
American (n=1350; 25 %), Asian (n=1350; 25 %),
and Hispanic/Latina (n=1350; 25 %) females. All par-
ticipants will be recruited at the time of their regular
mammography screening over a period of 2 years at 3
Kaiser Permanente of Northern California (KPNC) med-
ical centers and will have no history of prior clinical
CVD. A new, but rigorously validated densitometry
method will be used to estimate BAC mass (in milli-
grams [mg]) using digital mammograms.
(2) To assess associations of BAC mass with age, race/
ethnicity, family history of CVD, traditional and novel
CVD risk factors, renal function, reproductive health
factors, psychosocial factors, selected mineral metabo-
lism factors, selected medication use (statins and
nitrogen-containing bisphosphonates), breast size, and
sleep-related factors.
(3) To elucidate the role of BAC mass in the prediction of
coronary heart disease (CHD), cerebrovascular disease
(transient ischemic attack [TIA], hemorrhagic stroke,
and ischemic stroke), heart failure, peripheral vascular
disease, and total CVD and to determine whether adding
BAC mass to prediction model based on traditional risk
factors improves classification of risk for total CVD and
its components.
Despite existing evidence suggesting that BAC is a risk
factor for subclinical and clinical CVD, it is important to
note that all prior studies have relied on conventional (ie,
screen film) mammography. Further research is therefore
needed to examine the association of BAC with CVD risk
factors and CVD events using modern (ie, digital) mammo-
graphic techniques that have a much greater sensitivity
level. Furthermore, the BAC literature is based on the crude
assessment of absence vs presence of BAC and, to date, no
study has quantified BAC mass and its relationship with
CVD risk factors and events. In addition, there are signifi-
cant gaps in knowledge including the association of BAC
mass with other markers of subclinical CVD (ie, ankle-
brachial index), other breast characteristics (ie, breast vol-
ume), renal function, preventative medications that may
affect calcification (eg, statins or nitrogen-containing
bisphosphonate), psychosocial factors, mineral metabolism
factors (serum calcium, phosphorus, parathyroid hormone,
25-hydroxy-vitamin D concentrations), and sleep-related
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factors. Finally, studies like this one are needed to clarify
the potential incremental prognostic value of BAC pres-
ence and BAC mass for CVD and its components in a
contemporary era where widespread preventive efforts are
already underway.
The densitometry technique that will be used in the
MINERVA study to estimate calcium mass in mammograms
is described elsewhere [106••]. In brief, anthropomorphic
breast and vessel calcification phantoms were imaged using
a full-field digital mammography system. A calcium cali-
bration measurement was performed at each phantom thick-
ness and beam energy. The known (K) and measured (M)
calcium mass on phantoms 5 cm and 9 cm thick were tightly
related (M=0.964 K−0.288 mg; r=0.997, and M=1.004
K+0.324 mg; r=0.994, respectively). The results indicate
that accurate calcium mass measurements can be made
without correcting for scatter glare as long as careful calci-
um calibrations are made for each breast thickness. The
uncertainty in magnification is expected to cause up to
5 % and 15 % error in calcium mass for 5 cm and 9 cm
breast thicknesses, respectively. These results demonstrate the
feasibility and potential utility of our technique for accurate
BAC quantification in digital mammograms. In a second
study, we have demonstrated adequate reproducibility and
inter-reader agreement of the BAC mass measurement [107].
Standard full-field digital mammograms were acquired from
medial lateral oblique (MLO) and craniocaudal (CC) projec-
tions. Calcium mass was measured in each projection using
the technique developed in the previously described phantom
study (depicted in Fig. 2). In order to assess the reproducibility
of calcium measurement without added radiation exposure,
we compared calcium mass from 2 different projections
(Fig. 3a). The measured calcium masses in MLO (MMLO)
and CC (MCC) projections were highly correlated (r=0.95).
A plot of BAC mass measurements (average of MLO and CC
projections for right and left breasts) performed by the 2
observers is shown in Fig. 3b. These results indicate excellent
inter-reader agreement (intra-class r=0.94) and demonstrate
that our densitometry technique for quantifying BAC mass
using standard full-view digital mammography is highly
reproducible.
In this study, BAC was identified and regions of interest
were drawn manually (Fig. 2). To make this methodology
more easily adoptable by other groups and implemented in
clinical settings, it is desirable to automate this process. In
collaboration with 1 of the major manufacturers of mam-
mography systems (Hologic, Inc., Bedford MA), we are in
the process of evaluating a fully automated algorithm for
BAC detection and extraction from mammograms. There
are also other research groups pursuing a similar approach
Table 1 Summary of published studies of the association of BAC with CVD
First author, year Sample size Outcome[s] Findings
Cohort Studies
Van Noord et al. [61] 12,239 TIA/stroke, thrombosis, myocardial
infarction
Adjusted RR=1.4 for TIA/stroke, 1.5 for thrombosis,
1.8 for myocardial infarction
Kemmeren et al. [72] 12,239 CVD death, total mortality Adjusted RR=1.40 for CVD death, 1.30 for total mortality
Iribarren et al. [55] 12,761 Incident fatal or non-fatal CHD,
ischemic stroke, heart failure
Adjusted RR=1.32 for CHD, 1.41 for ischemic stroke,
1.52 for heart failure
Schnatz et al. [97] 1454 Incident CHD in 5 years Age-adjusted OR=2.2
Cross-sectional studies
Doerger et al. [98] 1803 Angiographic CAD Adjusted OR=1.4
Fiuza Ferreira et al. [99] 131 Angiographic CAD Adjusted OR=4.6
Henkin et al. [54] 319 Angiographic CAD Adjusted OR=1.0
Topal et al. [100] 123 Angiographic CAD P for contrast of Gensini score=0.05
Kataoka et al. [56] 1590 Prevalent CHD Adjusted OR=2.5
Maas et al. [57] 499 Coronary artery calcification Adjusted OR=2.1
Dale et al. [53] 645 Peripheral vascular disease Sensitivity and specificity of BAC for PVD=42 %
and 80 %
Dale et al. [51] 1000 Self-reported history of CAD Unadjusted OR=3.6
Yildiz et al. [104•] 54 Carotid IMT Multivariate β for presence of BAC=0.46 [P<0.001]
Ferreira et al. [101] 307 Global CVD Adjusted OR of CVD with BAC=8.1
Oliveira et al. [102] 80 Clinical CAD Adjusted OR of CAD with BAC=4.7
Sedighi et al. [63] 537 IMT and carotid plaque by ultrasound OR for carotid plaque=3.1
Ahn et al. [105••] 168 White matter (WMH) and periventricular
hyperintensity (PVH) on Brain MRI
Adjusted OR=6.7 for WMH and 9.0 for PVH
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[108–110]. The automated technique will completely elim-
inate the inter-reader variability. It can be combined with our
technique to automatically quantify calcium mass from
mammograms in a clinical setting. However, the technique
will require further optimization and validation before it can
be used. The proposed study will provide us the opportunity
to compare the results from readers and the fully automatic
algorithm.
Potential Public Health and Clinical Contributions
A very large proportion of women undergo screening mam-
mography on a regular basis after the age of 40. There are
minimal costs associated with reading and grading BAC.
MINERVA will shed light on the epidemiological associa-
tions between BAC mass and an extensive array of cova-
riates. More importantly, it will establish (for the first time)
the incremental utility of BAC mass for predicting clinical
CHD, cerebrovascular disease, heart failure, peripheral vas-
cular disease, and total CVD among women aged 60–
79 years. While we recognize that the densitometry method
to quantify BAC mass in digital mammograms that we have
developed for this proposal is novel and not yet universally
available, the transition to digital imaging is a reality in most
major university and community hospitals. Our methodolo-
gy to compute BAC mass can be easily adopted by other
groups and medical centers. Furthermore, we are in the
process of evaluating a fully automated algorithm for BAC
detection from mammograms. The eventual automation of
this technique will make its clinical implementation much
easier.
What are the clinical implications? First, the discovery of
BAC should trigger an investigation of risk factor levels and
subsequent treatment as needed to reduce those found to be
elevated. Second, a scenario where detecting extensive BAC
may be particularly useful in women at moderate cardiovas-
cular risk based on existing clinical risk algorithms. In this
instance, BAC may be a useful tool for reclassifying them
into the high risk group, where a more aggressive approach
may be warranted.
This epidemiological study is a necessary, intermediate
step to demonstrate clinical predictive utility of BAC mass.
The utility of coronary calcium (which requires a separate
CT scan of the heart) to significantly improve net reclassi-
fication for CHD has recently been demonstrated in the
MESA study [111]. If we are able to demonstrate meaning-
ful added risk assessment performance using BAC mass











































a bFig. 3 a. Scatter-plot of BAC
mass in 2 projections. b.
Scatter-plot of BAC mass by 2
observers
Fig. 2 Densitometry calcium mass measurement in mammograms
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above and beyond conventional risk factors (ie, at least 10 %
improvement in net reclassification with categories) [112], we
would then proceed to develop new risk estimation systems
for total CVD and for each of its components (CHD, cerebro-
vascular disease, peripheral vascular disease, and heart fail-
ure). First, we would incorporate the BAC mass score to
traditional risk factors (the Framingham risk score) and sec-
ond, we would add the BAC mass score to conventional risk
factors plus hs-CRP and family history of CHD (the Reynolds
risk score). After, we would seek collaborations to validate
these new algorithms in other cohorts. Whether the provision
of these new risk-estimation systems will result in benefits to
healthcare providers and individual patients, in term of reduc-
tions of risk factors and/or clinical outcomes, would require
further testing in clinical trials.
Assuming that BAC quantity is associated with an in-
creased risk of CVD events, if a woman is found to have
BAC, particularly highly elevated BAC mass, it should trigger
an investigation of cardiovascular risk factor profile (diabetes,
hypertension, lipid profile, inflammatory status) and this wom-
an should be treated more aggressively if 1 or more of these
risk factors are found to be present (in a similar fashion
proposed for CAC [113, 114]. We do not advocate the reverse,
that is, women presenting with risk factors being referred to
mammography. The beauty of mammography is that the indi-
cation already exists for the early detection of breast cancer.
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